Advanced in Essential Thrombocythemia

Johnson Lin

No. 92, Zhongshan North Road, 
TPQ, TW 
Advanced in Essential Thrombocythemia
No. 92, Zhongshan North Road, 
TPQ, TW 
OverviewLocationsClinical Research

Overview

Johnson Lin practices in Taiwan. Mr. Lin is rated as an Advanced expert by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Essential Thrombocythemia, Blood Clots, Myeloproliferative Neoplasms (MPN), and Metastatic Brain Tumor.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Essential Thrombocythemia.

Gender
Male

Locations

No. 92, Zhongshan North Road, TPQ 10449, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Zanidatamab, Tislelizumab, Trastuzumab, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Study Phase: Phase 3
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drugs: EndoTAG-1, Gemcitabine
Study Phase: Phase 3
A Long Term, Open-Label, Multi-Center Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain
A Long Term, Open-Label, Multi-Center Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain
Enrollment Status: Completed
Publish Date: March 18, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

26 Total Publications

Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 study.
Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 study.
Journal: Cancer
Published: November 06, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lin's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile